Lifetime Unit Economics And Global Expansion Will Support Stronger Long Term Profitability

Catalysts

About Chrysos

Chrysos provides PhotonAssay units and services for mineral analysis, primarily to mining companies and laboratory partners.

What are the underlying business or industry changes driving this perspective?

• Growing global deployment of PhotonAssay units, including new regions such as Chile and Suriname, increases the installed base that feeds into minimum monthly assay payments, supporting future revenue and EBITDA.
• The mix of revenue toward minimum monthly assay payments at 85% of PhotonAssay income provides higher visibility, while additional assay charges linked to sample volumes give upside potential to earnings as utilization changes.
• Expansion across the Americas and EMEA with a hub model and shared maintenance resources is expected to create operating efficiencies. This has the potential to support gross margin and net margin over time as the fleet grows.
• Development of the next generation XN unit, designed for lower installation, transport and maintenance requirements, points to a pathway for reduced unit level costs. This could support margins and cash generation per unit.
• A PhotonAssay unit cost profile just under A$4 million plus around A$400,000 of spares for assets expected to generate in excess of A$20 million in lifetime cash suggests unit economics that can support revenue and operating cash flow as more units are deployed.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Chrysos's revenue will grow by 33.2% annually over the next 3 years.
• Analysts assume that profit margins will increase from -12.4% today to 11.1% in 3 years time.
• Analysts expect earnings to reach A$17.3 million (and earnings per share of A$0.15) by about January 2029, up from A$-8.2 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting A$31.2 million in earnings, and the most bearish expecting A$14.0 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 72.6x on those 2029 earnings, up from -100.9x today. This future PE is greater than the current PE for the AU Professional Services industry at 20.5x.
• Analysts expect the number of shares outstanding to grow by 0.95% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.88%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• The business model leans heavily on minimum monthly assay payments as the backbone of revenue, so any long term slowdown in exploration activity or mine production, particularly across international regions that now represent 65% of total revenue, could reduce assay volumes and weaken the stability of PhotonAssay revenue and EBITDA.
• Geographic expansion into new markets such as Chile and Suriname increases complexity in tax, regulation and operations. Setbacks in new country entries or higher than expected ongoing costs for advisers, maintenance hubs and local teams could erode gross margins and net margins over time.
• The expectation that each PhotonAssay unit will generate in excess of A$20 million of lifetime cash relies on sustained utilisation and customer retention. If mining customers shift assay methods or reduce usage, unit economics could deteriorate and reduce long term operating cash flow and earnings.
• The next generation XN unit is intended to lower installation, transport and maintenance requirements. Delays in development, higher build costs or weaker customer acceptance could limit the expected improvement in direct costs per unit and weigh on future gross margin and cash generation per unit.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of A$8.62 for Chrysos based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of A$10.0, and the most bearish reporting a price target of just A$6.5.
  
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be A$156.3 million, earnings will come to A$17.3 million, and it would be trading on a PE ratio of 72.6x, assuming you use a discount rate of 6.9%.
  
• Given the current share price of A$7.12, the analyst price target of A$8.62 is 17.4% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.